Day: September 16, 2022

Karsa, Mawar;Kosciolek, Angelika;Bongers, Angelika;Mariana, Anna;Failes, Tim;Gifford, Andrew J.;Kees, Ursula R.;Cheung, Laurence C.;Kotecha, Rishi S.;Arndt, Greg M.;Haber, Michelle;Norris, Murray D.;Sutton, Rosemary;Lock, Richard B.;Henderson, Michelle J.;Somers, Klaartje published 《Exploiting the reactive oxygen species imbalance in high-risk pediatric acute lymphoblastic leukemia through auranofin》. The research results were published in《British Journal of Cancer》 in 2021.Safety of ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold The article conveys some information:

The prognosis for high-risk childhood acute leukemias remains dismal and established treatment protocols often cause long-term side effects in survivors. This study aims to identify more effective and safer therapeutics for these patients. A high-throughput phenotypic screen of a library of 3707 approved drugs and pharmacol. active compounds was performed to identify compounds with selective cytotoxicity against leukemia cells followed by further preclin. evaluation in patient-derived xenograft models. Auranofin, an FDA-approved agent for the treatment of rheumatoid arthritis, was identified as exerting selective anti-cancer activity against leukemia cells, including patient-derived xenograft cells from children with high-risk ALL, vs. solid tumor and non-cancerous cells. It induced apoptosis in leukemia cells by increasing reactive oxygen species (ROS) and potentiated the activity of the chemotherapeutic cytarabine against highly aggressive models of infant MLL-rearranged ALL by enhancing DNA damage accumulation. The enhanced sensitivity of leukemia cells towards auranofin was associated with lower basal levels of the antioxidant glutathione and higher baseline ROS levels compared to solid tumor cells. Our study highlights auranofin as a well-tolerated drug candidate for high-risk pediatric leukemias that warrants further preclin. investigation for application in high-risk pediatric and adult acute leukemias. And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase.Safety of ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

COA of Formula: C38H34NO2PIn 1999, Imbos, Rosalinde;Brilman, Mirjan H. G.;Pineschi, Mauro;Feringa, Ben L. published 《Highly Enantioselective Catalytic Conjugate Additions to Cyclohexadienones. [Erratum to document cited in CA131:228499]》. 《Organic Letters》published the findings. The article contains the following contents:

The corrected versions of references 10 and 11 are given. To complete the study, the researchers used (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine (cas: 201732-49-2) .

(11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(cas: 201732-49-2) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.COA of Formula: C38H34NO2P

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Product Details of 34031-32-8In 2021, Kim, Hyun Young;Choi, Young Jae;Kim, Sang Kyum;Kim, Hyunsung;Jun, Dae Won;Yoon, Kyungrok;Kim, Nayoun;Hwang, Jungwook;Kim, Young-Mi;Lim, Sung Chul;Kang, Keon Wook published 《Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome》. 《Communications Biology》published the findings. The article contains the following contents:

Demand for a cure of liver fibrosis is rising with its increasing morbidity and mortality. Therefore, it is an urgent issue to investigate its therapeutic candidates. Liver fibrosis progresses following ‘multi-hit’ processes involving hepatic stellate cells, macrophages, and hepatocytes. The NOD-like receptor protein 3 (NLRP3) inflammasome is emerging as a therapeutic target in liver fibrosis. Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluates the antifibrotic effect of auranofin in vivo and explores the underlying mol. mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. Moreover, hepatic stellate cell (HSC), bone marrow-derived macrophage (BMDM), kupffer cell, and hepatocyte are used to examine the underlying mechanism of auranofin. Auranofin potently inhibits activation of the NLRP3 inflammasome in BMDM and kupffer cell. It also reduces the migration of HSC. The underlying mol. mechanism was inhibition of cystine-glutamate antiporter, system Xc. Auranofin inhibits system Xc activity and instantly induced oxidative burst, which mediated inhibition of the NLRP3 inflammasome in macrophages and HSCs. Therefore, to the best of our knowledge, we propose the use of auranofin as an anti-liver fibrotic agent.((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) were involved in the experimental procedure.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects.Product Details of 34031-32-8

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Computed Properties of C25H26NOPIn 2002, Fairlamb, Ian J. S.;Lloyd-Jones, Guy C.;Vyskocil, Stepan;Kocovsky, Pavel published 《Analysis of stereochemical convergence in asymmetric Pd-catalysed allylic alkylation reactions complicated by halide and memory effects》. 《Chemistry – A European Journal》published the findings. The article contains the following contents:

A quant. two-term description of memory effects arising in Pd-catalyzed allylic alkylation reactions formally proceeding through ‘meso’-type π-allylpalladium intermediates is presented. The utility of this description (stereochem. convergence (s.c.) and global enantiomeric excess (ee_g)) is demonstrated by application to a series of Pd-catalyzed allylic alkylation reactions involving racemic cyclopentenyl esters. Anal. of such reactions, by employing a range of enantiomerically pure monophosphine ligands, reinforces the conclusion that selectivities (enantiomeric excess (ee) values) obtained under standard ‘benchmark’ type conditions may be very misleading when powerful memory effects are operative. By comparison of s.c. and ee for a given ligand/solvent combination under a range of related conditions, however, one may predict the limiting (‘latent’) selectivity that will be obtained when the memory effect is negated. This technique is exemplified with one particular ligand [I; wherein Z = NMe₂] for which a number of strategies were employed to find conditions that negate the memory effect and reveal the limiting selectivity of the ligand. These conditions give a higher limiting global selectivity than that obtainable by using standard diastereoisomer equilibration methods such as added halide. Thus, the anal. of s.c. vs. ee_g also allows subtle changes in selectivity to be discerned. The difference in limiting selectivity (chloride vs. non-chloride conditions) is proposed to arise through the nucleophilic attack of neutral monodentate vs. cationic bidentate complexes I (wherein Z = NMe₂, OMe). The experimental procedure involved many compounds, such as (S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole (cas: 167693-62-1) .

(S)-2-(2-(Diphenylphosphanyl)phenyl)-4-isobutyl-4,5-dihydrooxazole(cas: 167693-62-1) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.Computed Properties of C25H26NOP

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Pereira, Sarah A. P.;Bobbink, Felix D.;Dyson, Paul J.;Saraiva, M. Lucia M. F. S. published 《Automatic evaluation of cyclooxygenase 2 inhibition induced by metal-based anticancer compounds》 in 2021. The article was appeared in 《Journal of Inorganic Biochemistry》. They have made some progress in their research.Computed Properties of C20H36AuO9PS The article mentions the following:

An automatic methodol. based on micro sequential injection anal. coupled to a lab-on-valve system (termed μSIA-LOV) was developed and used to determine the ability of metal-based anticancer compounds to inhibit cyclooxygenase 2 (COX-2) activity. COX-2 may be involved in pathogenesis of cancer and it is overexpressed in several types of solid tumors. Since platinum-based compounds are extensively used in the treatment of cancer, and ruthenium compounds are considered as promising candidates for next generation of non-targeted anticancer drugs, it is interesting to establish whether COX-2 inhibition is relevant to their mode of action. The μSIA-LOV system was optimized and the IC50 values of each compound were calculated All the results present RSD values less than 2.5%. IC50 values of 9.7 ± 0.6μM to 207 ± 3μM were obtained, with the most active inhibitor for COX-2 being rofecoxib with the metal compounds exhibiting IC50 values in the range 13.7 ± 1.6 to 207 ± 3. The results obtained in this work provide significant information about the mechanism of the studied compounds, mostly ruthenium-based compounds, and the role of COX-2 in their mode of action. Moreover, this work confirmed the potential of the μSIA-LOV system as a simple, versatile, robust, and rapid anal. tool for automating the determination of IC50 values of metal-based compounds And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase.Computed Properties of C20H36AuO9PS

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Feng, Guang-Jing;Wang, Shuang-Shuang;Lv, Jian;Luo, Tao;Wu, Yuzhou;Dong, Hai published 《Improved Synthesis of 1-Glycosyl Thioacetates and Its Application in the Synthesis of Thioglucoside Gliflozin Analogues》. The research results were published in《European Journal of Organic Chemistry》 in 2021.Formula: C20H36AuO9PS The article conveys some information:

An improved method to synthesize 1-glycosyl thioacetates was developed, where per-O-acetylated glycoses were allowed to directly react with potassium thioacetate (KSAc) in the presence of BF₃ · Et₂O in Et acetate under mild conditions. This method not only overcomes the disadvantage of the traditional one-step method, which is that the odorous and toxic thioacetic acid has to be used, but also overcomes the disadvantage of the traditional two-step method, which is that the unstable intermediate, glycosyl halide, has to be synthesized from the per-O-acetylated glycose in advance. Based on this, the per-O-acetylated glucosyl disulfide and the per-O-acetylated glucosyl 1-thiol were efficiently synthesized in high yields (91% and 90% resp.) starting from per-O-acetylated glycoses in two-step without the need to isolate intermediate products. Through metal-catalyzed cross-coupling of per-O-acetylated glucosyl 1-thiol with aryl-iodide under very mild conditions, two thioglucoside gliflozin analogs were efficiently synthesized in high yields for the first time. These two thioglucoside gliflozin analogs I and II were further confirmed to be stable to hydrolysis of β-glucosidase. And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects.Formula: C20H36AuO9PS

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Yang, Zhibin;Huang, Sheng;Liu, Yu;Chang, Xingyu;Liang, Yanshan;Li, Xi;Xu, Zhongren;Wang, Shiyu;Lu, Yunlong;Liu, Yuan;Liu, Wukun published 《Biotin-Targeted Au(I) Radiosensitizer for Cancer Synergistic Therapy by Intervening with Redox Homeostasis and Inducing Ferroptosis》. The research results were published in《Journal of Medicinal Chemistry》 in 2022.Product Details of 34031-32-8 The article conveys some information:

The search for highly selective sensitizers with a novel mechanism for tumor targeting therapy is of considerable interest. In this work, we have developed a series of new biotin-targeted Au(I) complexes. Through systematic biol. evaluation and comparison, biotinylated Au(I) complex 3a containing a triphenylphosphine ligand was screened, as it realized both prominent efficient inhibition and selective cytotoxicity to cancer cells, and the effect was better than that of popularly used auranofin. Meanwhile, complex 3a, as a potent radiosensitizer, enhances anticancer effects in vitro and in vivo and has sensitization selectivity. From the action mechanism study, we provide evidence that complex 3a could intervene in redox homeostasis through targeted binding and strong suppression of thioredoxin reductase (TrxR) and induce the ferroptosis death process, enabling it to sensitize tumor cells to radiotherapy. Thus, complex 3a has enormous potential as an efficient and specific radiosensitizing agent in cancer therapy. And ((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) was used in the research process.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress.Product Details of 34031-32-8

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Gonzalez-Esguevillas, Maria;Pascual-Escudero, Ana;Adrio, Javier;Carretero, Juan C. published 《Highly selective copper-catalyzed asymmetric [3+2] cycloaddition of azomethine ylides with acyclic 1,3-dienes》 in 2015. The article was appeared in 《Chemistry – A European Journal》. They have made some progress in their research.COA of Formula: C48H28F24O4P2 The article mentions the following:

The first examples of the catalytic asym. 1,3-dipolar cycloaddition of azomethine ylides with acyclic activated 1,3-dienes/1,3-enynes was described. Under copper catalysis, a selective cycloaddition at the terminal γ,δ-C=C bond was observed In addition, depending on the ligand used, either the exo or endo adduct of pyrrolidines e.g.I [Ar = C₆H₅, 4-MeC₆H₄, 2-BrC₆H₄, etc.] could be obtained with high selectivity. Under appropriate reaction conditions, the acyclic 1,6-addition product was detected, suggesting a stepwise mechanism. The resulting pyrrolidines were suitable substrates for further access to polycyclic systems, as highlighted by the preparation of hexahydrochromeno[4,3-b]pyrrole and the tetracyclic core of the alkaloid gracilamine.(R)-2,2′-Bis[bis(3,5-trifluoromethylphenyl)phosphino]-4,4′,6,6′-tetramethoxy)-1,1′-biphenyl (cas: 1365531-84-5) were involved in the experimental procedure.

(R)-2,2′-Bis[bis(3,5-trifluoromethylphenyl)phosphino]-4,4′,6,6′-tetramethoxy)-1,1′-biphenyl(cas: 1365531-84-5) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.COA of Formula: C48H28F24O4P2

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

HPLC of Formula: 34031-32-8In 2021, Xie, Ming-Zhang;Guo, Chun;Dong, Jia-Qi;Zhang, Jie;Sun, Ke-Tao;Lu, Guang-Jian;Wang, Lei;Bo, De-Ying;Jiao, Lu-Yang;Zhao, Guo-An published 《Glyoxal damages human aortic endothelial cells by perturbing the glutathione, mitochondrial membrane potential, and mitogen-activated protein kinase pathways》. 《BMC Cardiovascular Disorders》published the findings. The article contains the following contents:

Exposure to glyoxal, the smallest dialdehyde, is associated with several diseases; humans are routinely exposed to glyoxal because of its ubiquitous presence in foods and the environment. The aim of this study was to examine the damage caused by glyoxal in human aortic endothelial cells. Cell survival assays and quant. fluorescence assays were performed to measure DNA damage; oxidative stress was detected by colorimetric assays and quant. fluorescence, and the mitogen-activated protein kinase pathways were assessed using western blotting. Exposure to glyoxal was found to be linked to abnormal glutathione activity, the collapse of mitochondrial membrane potential, and the activation of mitogen-activated protein kinase pathways. However, DNA damage and thioredoxin oxidation were not induced by dialdehydes. Intracellular glutathione, members of the mitogen-activated protein kinase pathways, and the mitochondrial membrane potential are all critical targets of glyoxal. These findings provide novel insights into the mol. mechanisms perturbed by glyoxal, and may facilitate the development of new therapeutics and diagnostic markers for cardiovascular diseases.((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold (cas: 34031-32-8) were involved in the experimental procedure.

((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-thio)(triethylphosphine)gold(cas: 34031-32-8) is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects.HPLC of Formula: 34031-32-8

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis

Recommanded Product: (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amineIn 1999, Imbos, Rosalinde;Brilman, Mirjan H. G.;Pineschi, Mauro;Feringa, Ben L. published 《Highly Enantioselective Catalytic Conjugate Additions to Cyclohexadienones》. 《Organic Letters》published the findings. The article contains the following contents:

Enantioselective copper phosphoramidite-catalyzed conjugate addition of dialkylzinc reagents (R₂Zn) to several 4,4-disubstituted cyclohexadienones was achieved with diastereomeric ratios of up to 99/1 and enantiomeric excess of up to 99%. A catalyst generated from copper triflate and (S)-N,N-bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine showed high levels of stereoselectivity in the 1,4-addition to sym. dienones. The experimental procedure involved many compounds, such as (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine (cas: 201732-49-2) .

(11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(cas: 201732-49-2) is a compound of chiral-phosphine-ligands. At present, the synthesis of new chiral phosphines designed specifically for nucleophilic organocatalysis remains a significant challenge.Recommanded Product: (11bS)-2,6-Dimethyl-N,N-bis(1-phenylethyl)dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine

Reference:
Phosphine ligand,
Chiral phosphines in nucleophilic organocatalysis